Navigation Links
CEL-SCI Expands H1N1 Flu Virus Work
Date:8/18/2009

and.

For more information, please visit www.cel-sci.com.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
2. CEL-SCI Posts New Corporate Presentation to Website
3. CEL-SCI Corporation Releases Letter to Shareholders
4. CEL-SCI Corporation Releases Letter to Shareholders
5. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
6. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
7. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
8. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. CEL-SCI Corporation Announces 2007 Financial Results
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...OLNSHIRE,Ill.,Nov.23/PRNewswire/--Sarnova,Inc.,the...ductsintheemergencymedicalservices(EMS)andrespirat...cutivestoitsseniormanagementteam.Thenewexecutivesi...Hill,executivevicepresidentandgeneralcounsel;Steve...itaille,executivevicepresidentofcorporatedevelopme...
(Date:11/23/2009)...ANAPOLIS,Nov.23/PRNewswire/--AMDLASERSannouncedthi...leducationbypartneringwithprestigiousindustry-lead...yAMDLASERS,willbetheexclusivesofttissuediodelaseru...charetargetedtothetop2%ofdentists. ,, (Photo: h...9 ) ,, "ItiswithgreatpleasurethatIproudlyannoun...
(Date:11/23/2009)...CETON,N.J.,Nov.23/PRNewswire-FirstCall/--Pharmasse...ntofCohort2,ledbyitspartnerRoche(SWX:ROG.VX;RO.S,O...1and4patientsintheongoingphase2btrialofRG7128,afir...hetreatmentofchronichepatitisCvirus(HCV)infection....pendentDataMonitoringCommittee(DMC)ofallavailables...
Breaking Medicine Technology:Sarnova Expands Senior Management Team 2AMD LASERS Announces New Partnership with Dr. Larry Rosenthal and Aesthetic Advantage 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4IPRO Secures Special NY Funding to Coordinate Care for Patients with Diabetes 58764 1IPRO Secures Special NY Funding to Coordinate Care for Patients with Diabetes 58764 2Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 5191 1Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 5191 2Caraco Pharmaceutical Laboratories Ltd Closes Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram oxala 5189 1Caraco Pharmaceutical Laboratories Ltd Closes Asset Purchase Agreement with Forest Laboratories Inc to Settle Lexapro 28R 29 28escitalopram oxala 5189 2
...Void in the Local Treatment of Oral Candidiasis in...SBORO, N.J., Dec. 5 RHEI Pharmaceuticals, Inc. to...bozole, a locally active antifungal with low dose ...been initiated in China. This will be the last cl...rug Application (NDA) to the State Food and Drug A...
...c. 4 Long-term data published in,EuroIntervention...Area (MVA),after repair with the MitraClip(R) syst...ociated with clinically significant mitral stenosi...of the patients treated with the,MitraClip(R) syst...ths no,important differences were reported between...
Other Medicine Technology:RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4
(Date:11/24/2009)... NCL Security Launches EyeCentral Remote Video Pla...ing Monthly Revenue for Central Stations and Secur...xas (PRWEB) November 24, 2009 -- NCL Security Laun...rity Industry to Generate Recurring Monthly Revenu...quot;Integrated security systems has been and stil...
(Date:11/24/2009).../PRNewswire-USNewswire/--Newpeer-revieweddatafindi...nsinfectedwithchronichepatitisCvirushavereceivedan...atCongressneedstomoveurgentlyonbipartisanlegislati...veillanceefforts,the NationalViralHepatitisRoundta...congressionalaction,millionsofAmericansinfectedwit...
(Date:11/23/2009)...iversity of Michigan determined that only 663,000 ...patitis C virus (HCV) infection received antiviral...ppear to be declining, in part because only half o...sturbing trend continues, by 2030 less than 15% of...y antiviral therapy. This study, the first to ana...
(Date:11/23/2009),, NEWYORK,Nov.23/PRNewswire/--Livingwithchronicpaincanbedifficult-andthestressoftheholidayseasoncanprovetobequitechallengingforthoselivingwithpain. ,, ListentothisreportfromPfizerInc.at: ,
(Date:11/23/2009)...the hook for the high cost of drug advertising tha...tudy led by a University of British Columbia healt...ay in the Archives of Internal Medicine , examine...ing drug also known by the trade name Plavix used ...e. The drug was selected to study the impact of ad...
Breaking Medicine News(10 mins):Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2
...ems, Inc.,(NYSE: DST ) will release its financial...08, on Tuesday, July 22, 2008, after the close of ...any will host a conference call on Wednesday, July...rnational,callers, the dial-in number is (612) 234...
...iming June,20 Donated Dental Services (DDS) Progra...l acknowledged the significant charitable contribu...) members across the state., "We are extremely pl...he inception of the Pennsylvania DDS,program in 19...
... immune system , , TUESDAY, June 24 (Healt...etastatic colon cancer appears to work in mice, r...operty: It acts on the immune system in the intes...one and one in the gut," said lead researcher Dr. ...
... Protect Patient Access To Community,Pharmacies, ...entatives voted 355 to 59 in favor of H.R. 6331, w...care bill contains three critical,provisions for c...ment that would have driven thousands of,community...
...bare metal devices, study suggests , , TUE...ho got drug-coated stents did better than those wh...tudy found. , But it isn,t a simple either-or issu... October 2002 and March 2003, when only bare-metal...
...ordering supplies has helped Geisinger cut $30 mil...rs, made it easier to recall medications in the ev...uplication of many products. , Geisinger,s Supp...ovation Award from the Premier healthcare alliance...
Other Medicine News:Health News:DST Systems, Inc. Announces Notification of Earnings Release Date 2Health News:Governor Lauds Pennsylvania Dental Association Member Participation in Donated Dental Services Program 2Health News:Vaccine Stops Colon Cancer's Spread in Mice 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 3Health News:Geisinger saves millions in medical dollars through better supply management 2
...pping System combines the legendary accuracy of th... software. It integrates seamlessly into your EP ...e your clinical capabilities in an easy-to-upgrade...he intended use of the CARTO XP System is catheter...
Model 3077 Single-Chamber Temporary Pacemaker
...'s broadest line of endocardial temporary pacing c...able in both torque control and flow-directed mode...ode spacing options. The Pacel Bipolar Pacing Cat...us right ventricular pacing. Prophylactic system...
Novacor LVAS
Medicine Products: